Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development expenses	$ 6,448,528	$ 4,352,987	$ 20,297,066	$ 13,275,947
General and administrative expenses	4,071,158	2,926,209	12,341,207	9,575,122
Total operating expenses	10,519,686	7,279,196	32,638,273	22,851,069
Loss from operations	(10,519,686)	(7,279,196)	(32,638,273)	(22,851,069)
Interest income (expenses), net
Interest income	739,404	252,073	2,219,399	332,318
Interest expense	(1,068,887)	(397,327)	(3,031,129)	(397,326)
Interest income (expenses), net	(329,483)	(145,254)	(811,730)	(65,008)
Loss before income taxes	(10,849,169)	(7,424,450)	(33,450,003)	(22,916,077)
Benefit for income taxes	0	0	1,406,021	1,198,905
Net loss	(10,849,169)	(7,424,450)	(32,043,982)	(21,717,172)
Comprehensive loss	$ (10,849,169)	$ (7,424,450)	$ (32,043,982)	$ (21,717,172)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.35)	$ (0.26)	$ (1.04)	$ (0.76)
Net loss per share, diluted (in dollars per share)	$ (0.35)	$ (0.26)	$ (1.04)	$ (0.76)
Weighted average common shares outstanding, basic (in shares)	30,910,520	28,458,688	30,715,458	28,452,997
Weighted average common shares outstanding, diluted (in shares)	30,910,520	28,458,688	30,715,458	28,452,997